The prognostic relevance of tumor hypoxia markers in resected carcinoma of the gallbladder

European Journal of Surgical Oncology

Volumn 37, Issue 1, 2011, Pages 80-86

  Sergeant, G ^a   Lerut, E ^a   Ectors, N ^a   Hendrickx, T ^a   Aerts, R ^a   Topal, B ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Gallbladder; Hypoxia; Malignancy; Surgery; Survival

Indexed keywords

CARBONATE DEHYDRATASE IX; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHOLECYSTECTOMY; CLINICAL ARTICLE; DISEASE MARKER; FEMALE; FOLLOW UP; GALLBLADDER CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; STAINING; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 78650273777     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2010.10.007     Document Type: Article

References (28)

1. M.T. Carriaga, and D.E. Henson Liver, gallbladder, extrahepatic bile ducts, and pancreas Cancer 75 1 Suppl 1995 Jan 1 171 190
2. J.H. Donohue, A.K. Stewart, and H.R. Menck The national cancer data base report on carcinoma of the gallbladder, 1989-1995 Cancer 83 12 1998 Dec 15 2618 2628
3. G. Miller, and W.R. Jarnagin Gallbladder carcinoma Eur J Surg Oncol 34 3 2008 Mar 306 312
4. J.A. Bertout, S.A. Patel, and M.C. Simon The impact of O2 availability on human cancer Nat Rev Cancer 8 12 2008 Dec 967 975
5. I.S. Song, A.G. Wang, and S.Y. Yoon Regulation of glucose metabolism-related genes and VEGF by HIF-1alpha and HIF-1beta, but not HIF-2alpha, in gastric cancer Exp Mol Med 41 1 2009 Jan 31 51 58
6. R.E. Airley, and A. Mobasheri Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics Chemotherapy 53 4 2007 233 256
7. M.H. Bui, D. Seligson, and K.R. Han Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy Clin Cancer Res 9 2 2003 Feb 802 811
8. J.K. Rho, Y.J. Choi, and J.K. Lee Gefitinib circumvents hypoxia-induced drug resistance by the modulation of HIF-1alpha Oncol Rep 21 3 2009 Mar 801 807
9. F. Green, editor AJCC cancer staging manual 6th ed 2002 Springer-Verrlag New York
10. S.P. Shih, R.D. Schulick, and J.L. Cameron Gallbladder cancer: the role of laparoscopy and radical resection Ann Surg 245 6 2007 Jun 893 901
11. E. Dixon, C.M. Vollmer Jr., and A. Sahajpal An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center Ann Surg 241 3 2005 Mar 385 394
12. A.F. Hezel, and A.X. Zhu Systemic therapy for biliary tract cancers Oncologist 13 4 2008 Apr 415 423
13. N.S. Azad, E.M. Posadas, and V.E. Kwitkowski Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity J Clin Oncol 26 22 2008 Aug 1 3709 3714
14. T. Ito, Y. Noguchi, and S. Satoh Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage Mod Pathol 11 5 1998 May 437 443
15. P. Parente, A. Coli, and G. Massi Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions J Exp Clin Cancer Res 27 2008 34
16. Y.W. Kim, Y.K. Park, and T.Y. Yoon Expression of the GLUT1 glucose transporter in gallbladder carcinomas Hepatogastroenterology 49 46 2002 Jul-Aug 907 911
17. P.H. Maxwell, G.U. Dachs, and J.M. Gleadle Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth Proc Natl Acad Sci U S A 94 15 1997 Jul 22 8104 8109
18. T. Yamamoto, Y. Seino, and H. Fukumoto Over-expression of facilitative glucose transporter genes in human cancer Biochem Biophys Res Commun 170 1 1990 Jul 16 223 230
19. M. Younes, L.V. Lechago, and J.R. Somoano Immunohistochemical detection of Glut3 in human tumors and normal tissues Anticancer Res 17 4A 1997 Jul-Aug 2747 2750
20. P. Swietach, R.D. Vaughan-Jones, and A.L. Harris Regulation of tumor pH and the role of carbonic anhydrase 9 Cancer Metastasis Rev 26 2 2007 Jun 299 310
21. C.A. Brewer, S.Y. Liao, and S.P. Wilczynski A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN Gynecol Oncol 63 3 1996 Dec 337 344
22. J. Saarnio, S. Parkkila, and A.K. Parkkila Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity J Histochem Cytochem 46 4 1998 Apr 497 504
23. J.R. Turner, R.D. Odze, and C.P. Crum MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker Hum Pathol 28 6 1997 Jun 740 744
24. J. Rak, J.L. Yu, R.S. Kerbel, and B.L. Coomber What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res 62 7 2002 Apr 1 1931 1934
25. A. Franovic, L. Guaratnam, and K. Smith Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer Proc Natl Acad Sci U S A 104 32 2007 Aug 7 13092 13097
26. N. Pore, Z. Jiang, and A. Gupta EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms Cancer Res 66 6 2006 Mar 15 3197 3204
27. E. Van Cutsem, C.H. Kohne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 14 2009 Apr 2 1408 1417
28. J. Tabernero, E. Van Cutsem, and E. Diaz-Rubio Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer J Clin Oncol 25 33 2007 Nov 20 5225 5232